Symbols

KYMR

Kymera Therapeutics·NASDAQ

--(--)

Signals Analysis

Bullish signal 3

Bearish signal 2

Consensus Rating "Strong Buy"

Ample Liquidity

High Gross Profit Margin

EPS Below Expectations

Revenue Below Expectations

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About KYMR

Kymera Therapeutics, Inc.

A clinical-stage biopharmaceutical company that delivering novel small molecule protein degrader medicines used to degrade disease-causing proteins

Industry

Biological Technology

Established Date

05/25/2017

Listing Date

08/21/2020

Exchange

NASDAQ Stock Exchange

Full-time Employees

238

Fiscal Year Ends

12-31

Website

www.kymeratx.com

Security Type

Common stock

Office address

500 North Beacon Street, 4th Floor, Watertown, Massachusetts 02472

Business

Introduction

Kymera Therapeutics, Inc., a limited liability company, was incorporated under the laws of the State of Delaware on May 25, 2017. The company is a biopharmaceutical company focused on the discovery and development of novel small molecule therapies that selectively degrade disease-causing proteins using the body's own natural protein degradation system. The company has a proprietary targeted protein degradation platform called Pegasus, which is able to discover highly selective small molecule protein degradation agents with strong activity on systemic disease-causing proteins. The company believes that its small molecule protein degraders have significant advantages over existing therapies, and can treat large areas of the human genome that were previously inaccessible to traditional therapies. The company focuses on biological pathways that have been clinically validated but whose key biological nodes/proteins have not been drug-targeted or whose drug targeting is not effective.

Company Financials

EPS

KYMR has released its 2025 Q4 earnings. EPS was reported at -0.97, versus the expected -0.79, missing expectations. The chart below visualizes how KYMR has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

KYMR has released its 2025 Q4 earnings report, with revenue of 2.87M, reflecting a YoY change of -61.18%, and net profit of -86.98M, showing a YoY change of -22.94%. The Sankey diagram below clearly presents KYMR's revenue sources and cost distribution.